Sunday, January 11, 2009
RANBAXY GETS USFDA APPROVAL FOR GLIADEL
Ranbaxy Laboratories Limited announced that the company had received USFDA approval for marketing of Gliadel (polifepro 20 with Carmustine implant) Wafer for treatment of highly malignant gliomas & recurrent glioblastoma multiforme. Ranbaxy laboratories limited has signed license agreemetn withBioPro Pharmaceutical Inc, to promote and market Gliadel Wafers in India.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment